20-F: Apollomics Inc. Files 20-F Annual Report, Cites Liquidity Concerns Despite Pipeline Progress

Apollomics Inc.'s 20-F filing reveals ongoing net losses and a need for additional capital, despite advancements in its oncology pipeline and a recent licensing agreement.

Summary

• Apollomics Inc., a clinical-stage biopharmaceutical company, filed its 20-F annual report, highlighting its focus on oncology therapies.
• The company has a pipeline of product candidates, including vebreltinib, APL-102, and APL-122, targeting difficult-to-treat cancers.
• The report indicates that Apollomics has incurred significant net losses since its inception and anticipates continuing losses for the foreseeable future.
• For the year ended December 31, 2024, the company reported a net loss of $53.9 million and used $28.7 million in net cash for operating activities.
• The company estimates it has sufficient liquidity to continue as a going concern through at least December 31, 2025, based on its operating plan and expected upfront payment from LaunXP International.
• Apollomics acknowledges the need for additional capital through equity, debt, or strategic partnerships.
• A recent licensing agreement with LaunXP International for vebreltinib in Asia (excluding mainland China, Hong Kong, and Macau) is expected to provide $10 million upfront.
• The company is focusing future vebreltinib clinical development on NSCLC patients with Met amplification.
• In May 2024, GlycoMimetics, Apollomics' licensor of uproleselan in China, announced negative results from its pivotal Phase 3 study, leading Apollomics to close its own Phase 3 bridging study early and record an impairment loss of $10.0 million.
• The company is subject to complex and rapidly evolving laws and regulations in China, which could affect its business operations.
• The company identified a material weakness and three significant deficiencies in its internal control over financial reporting as of December 31, 2023, but determined that the material weakness and two of the significant deficiencies were remediated as of December 31, 2024.
• The company is taking advantage of certain exemptions from disclosure requirements available to emerging growth companies and foreign private issuers.
• On November 25, 2024, the Company completed a 100 to 1 reverse split of its Class A Ordinary Shares.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive developments in the pipeline and a new licensing agreement, the company's financial situation is concerning due to ongoing losses and the need for additional capital. The negative results from the GlycoMimetics study and the impairment loss further dampen the outlook.

Positives

• Apollomics has a pipeline of product candidates targeting difficult-to-treat cancers.
• The company estimates it has sufficient liquidity to continue as a going concern through at least December 31, 2025.
• A licensing agreement with LaunXP International is expected to provide $10 million upfront.
• The company is focusing future vebreltinib clinical development on NSCLC patients with Met amplification.
• The company determined that the material weakness and two of the significant deficiencies in its internal control over financial reporting were remediated as of December 31, 2024.

Negatives

• Apollomics has incurred significant net losses since its inception and anticipates continuing losses.
• The company acknowledges the need for additional capital through equity, debt, or strategic partnerships.
• An impairment loss of $10.0 million was recorded due to negative results from GlycoMimetics' uproleselan study.
• The company is focusing future vebreltinib clinical development on NSCLC patients with Met amplification, which is confirmed by a genetic test which is not part of the standard genetic testing done for this patient population.
• The company identified a material weakness and three significant deficiencies in its internal control over financial reporting as of December 31, 2023, but determined that one significant deficiency remained as of December 31, 2024.

Risks

• The company's future profitability is dependent on the development of its pipeline products.
• The company may not be able to obtain licenses to promising oncology programs for the American, European and/or Chinese markets on desirable terms or at all.
• The company may be involved in claims, disputes, litigation, arbitration or other legal proceedings in the ordinary course of business, and any claims or proceedings against us could be costly and time-consuming to defend.
• The company is subject to complex and rapidly evolving laws and regulations in China, which could affect its business operations.
• The company may not be able to comply with the continued listing standards of Nasdaq or any other exchange.
• The trading price of the company's securities has been and is likely to continue to be volatile, which could result in substantial losses to holders of its securities.
• The company is incurring significant increased expenses and administrative burdens as a public company.
• The company qualifies as an emerging growth company and a foreign private issuer within the meaning of the Securities Act, and we take advantage of certain exemptions from disclosure requirements available to emerging growth companies and foreign private issuers, that could make our securities less attractive to investors and may make it more difficult to compare our performance to the performance of other public companies.

Future Outlook

Apollomics expects to continue to incur net losses for the foreseeable future and will require additional capital to continue as a going concern.

Industry Context

The announcement highlights the competitive landscape of the oncology drug development industry, with numerous companies pursuing similar targets and indications. The success of Apollomics depends on its ability to differentiate its product candidates and secure regulatory approvals in a timely manner.

Comparison to Industry Standards

• The report mentions capmatinib and tepotinib, two c-Met inhibitors approved for NSCLC with Met Exon 14 skipping alterations, providing a benchmark for vebreltinib's potential.
• The FDA's concerns regarding clinical data collected exclusively in China, as seen with sintilimab, highlight the importance of diverse clinical trial populations for regulatory approval.

Legal Proceedings

• The company is defending a Writ and Statement of Claim issued in the Grand Court of the Cayman Islands by one investment manager for two minority investors in the company, related to alleged redemption requests.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional equity securities.
• Employees may be affected by potential cost reduction measures and changes in the company's strategic focus.
• Patients may benefit from the development of new oncology therapies, but clinical trials are subject to risks and uncertainties.
• Suppliers and creditors may be affected by the company's financial condition and ability to meet its obligations.

Next Steps

• Continue clinical development of vebreltinib, focusing on NSCLC patients with Met amplification.
• Seek strategic partnerships for immuno-oncology product candidates.
• Pursue regulatory approval for vebreltinib in the United States and other jurisdictions.
• Monitor and manage compliance with evolving laws and regulations in China.
• Implement and maintain effective internal control over financial reporting.

Key Dates

Keywords

vebreltinib, oncology, clinical trials, biopharmaceutical, APLM, APLMW, NSCLC, capital raise, FDA, NMPA